Chromophil Renal Cell Carcinoma - 22 Studies Found
| Recruiting |
: Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer :
: |
| Active, not recruiting |
: Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer :
|
| Terminated |
: Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer :
|
| Active, not recruiting |
: Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant :
|
| Active, not recruiting |
: Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer :
|
| Completed |
: A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma :
|
| Completed |
: Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer :
|
| Completed |
: Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors :
|
| Completed |
: Bortezomib in Treating Patients With Metastatic Kidney Cancer : Kidney Cancer : 2006-01-12 : Drug: bortezomib |
| Completed |
: Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer : Kidney Cancer : 2006-11-16 :
|